Pharmacotherapy of gout – modern approaches and prospects
https://doi.org/10.14412/1996-7012-2021-4-107-112
Abstract
The article discusses modern approaches to the gout treatment, presented in foreign and domestic clinical guidelines. While the use of urate-lowering therapy for gout is a necessary and highly effective strategy, in the case of asymptomatic hyperuricemia, the benefits of this approach are not clear. The safety and efficacy of colchicine, as well as its cardioprotective properties, were noted in comorbid patients suffering from gout and cardiovascular diseases. Comparative data on safety and efficacy of the main urate-lowering drugs, allopurinol and febuxostat, are presented. It has been shown that, according to recent studies, febuxostat is more effective than allopurinol in normalizing serum uric acid levels, is not inferior in its cardio safety and is characterized by a lower incidence of other adverse reactions.
About the Authors
P. A. Lebedev
Samara State Medical University
Russian Federation
Russian Federation
89, Chapayevskaya St., Samara 443099
A. A. Garanin
Samara State Medical University
Russian Federation
Russian Federation
Andrey Alexandrovich Garanin
89, Chapayevskaya St., Samara 443099
N. L. Novichkova
Samara State Medical University
Russian Federation
Russian Federation
89, Chapayevskaya St., Samara 443099
References
1. Gout. Clinical recommendations, 2018. http://cr.rosminzdrav.ru/recomend/251_1
2. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Aug;73(8):1470-6. doi: 10.1136/annrheumdis-2013-204647
3. Elfishawi MM, Zleik N, Kvrgic Z, et al. The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-Based Study Over 20 Years. J Rheumatol. 2018 Apr;45(4):574-9. doi:10.3899/jrheum.170806
4. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoi meditsiny. 2018;46(1):32-9. (In Russ.).
5. Zhu Y, Bhavik J, Pandya BJ, et al. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 20072008. Arthritis Rheum. 2011 Oct;63(10):3136-41. doi: 10.1002/art.30520
6. Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019; 9:e026677. doi:10.1136/bmjopen-2018-026677
7. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015 Apr; 74(4):661-7. doi: 10.1136/annrheumdis2013-204463. Epub 2014 Jan 15.
8. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020 Jan;79(1):31-8. doi: 10.1136/annrheumdis-2019-215315. Epub 2019 Jun 5.
9. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
10. Ni Q, Lu X, Chen C, et al. Risk factors for the development of hyperuricemia. Medicine (Baltimore). 2019 Oct;98(42):e17597. doi: 10.1097/MD.0000000000017597.
11. Konta T, Ichikawa K, Kawasaki R, et al. Association between serum uric acid levels and mortality: a nationwide community-based cohort study. Sci Rep. 2020 Apr 8; 10(1):6066. doi: 10.1038/s41598-020-63134-0
12. Efstathiadou A, Gill D, McGrane F, et al. Genetically Determined Uric Acid and the Risk of Cardiovascular and Neurovascular Diseases: A Mendelian Randomization Study of Outcomes Investigated in Randomized Trials. J Am Heart Assoc. 2019 Sep 3;8(17):e012738. doi: 10.1161/JAHA.119.012738. Epub 2019 Aug 23.
13. Chazova IE, Zhernakova JV, Kisliak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019;4(16):8-21. doi: 10.26442/2075082X.2019.4.190686
14. Yokose C, Lu N, Xie H, et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. CMAJ. 2019 Sep 30;191(39):E1070-E1077. doi: 10.1503/cmaj.190339
15. Brucatoa A, Ciancib F, Carnovale C. Management of hyperuricemia in asymptomatic patients: A critical appraisal. Eur J Intern Med. 2020 Apr;74:8-17. doi: 10.1016/j.ejim.2020.01.001. Epub 2020 Jan 15.
16. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015 Apr; 74(4):661-7. doi: 10.1136/annrheumdis2013-204463
17. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012 Jan 12;344:d8190. doi: https: 10.1136/bmj.d8190
18. Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 Oct 23;138(17):e595-e616. doi: 10.1161/CIR.0000000000000601
19. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-60. doi: 10.1002/acr.24180. Epub 2020 May 11.
20. Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018 Mar;28(2): 339-44. doi: 10.1080/14397595.2017.1318467
21. Oh YJ, Moon KW. Combined Use of Febuxostat and Colchicine Does Not Increase Acute Hepatotoxicity in Patients with Gout: A Retrospective Study. J Clin Med. 2020 May 15;9(5):1488. doi: 10.3390/jcm9051488
22. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of Action of Colchicine in the Treatment of Gout. Clin Ther. 2014 Oct;36(10): 1465-79. doi: 10.1016/j.clinthera.2014.07.017
23. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-10. doi: 10.1016/j.jacc.2012.10.027
24. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-505. doi: 10.1056/NEJMoa1912388
25. Katsanos AH, Palaiodimou L, Price C, et al. Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. Eur J Neurol. 2020 Jun;27(6):1035-8. doi: 10.1111/ene.14198
26. Tran TH, Pham JT, Shafeeq H, et al. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013 Jul;33(7): 744-53. doi: 10.1002/phar.1265
27. Eliseev MS. Comments on the updated recommendations of the American College of Rheumatology for the treatment of gout. Urate-lowering drugs (part 1). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(3):117-124. (In Russ.). doi: 10.14412/1996-7012-2020-3-117-24
28. Kamel B, Graham GG, Williams KM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet. 2017 May;56(5):459-75. doi: 10.1007/s40262-016-0466-4
29. Schumacher HR, Becker MA, Wortmann RL, et al. The FOCUS trial 48-month interim analysis: long-term clinical. outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open label extension study [abstract no. OP0130]. Ann Rheum Dis. 2006;65(2):93. doi: 10.26442/20751753.2018.12.180108
30. White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13): 1200-10. doi: 10.1056/NEJMoa1710895
31. Choi H, Neogi T, Stamp L, et al. Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert. Arthritis Rheumatol. 2018 Nov;70(11):1702-9. doi: 10.1002/art.40583.
32. FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat. https://www.fda.gov/drugs/drug-safety-andavailability/fda-drug-safety-communicationfda-evaluate-increased-risk-heart-relateddeath-and-death-all-causes
33. Cicero AF, Cosentino ER, Kuwabara M, et al. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. 2019 Sep;14(6): 949-56. doi: 10.1007/s11739-019-02070-y
34. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020 Nov 28;396(10264):1745-57. doi: 10.1016/S0140-6736(20)32234-0
35. Bardin T, Chales G, Pascart T, et al. Risk of cutaneous adverse events with febuxostate treatment in patients with skin reaction to allopurinol. Joint Bone Spine. 2016 May;83(3): 314-7. doi: 10.1016/j.jbspin.2015.07.011. Epub 2015 Dec 18.
36. Lin CW, Huang WI, Chao PH. Risk of cutaneous adverse reactions associate with allopurinol or febuxostat in real world patients:a real world study. Int J Clin Pract. 2019 May;73(5):e13316. doi: 10.1111/ijcp.13316. Epub 2019 Feb 28.
37. Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019 Mar; 51(3):467-73. doi: 10.1007/s11255-018-2051-2
38. Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther. 2020 Jan;58(1): 21-8. doi: 10.5414/CP203466
39. Novikova AM, Eliseev MS. The place of febuxostat in the treatment of gout. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(3):150-5. (In Russ.). doi: 10.14412/1996-7012-2020-3-150-155
40. Juge PA, Truchetet ME, Pillebout E, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017 Oct;84(5):595-8. doi: 10.1016/j.jbspin.2016.09.020
41. Liu X, Wang H, Ma R, et al. The uratelowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol. 2019 Mar;23(3):362-70. doi: 10.1007/s10157018-1652
Review
For citations:
Lebedev PA, Garanin AA, Novichkova NL. Pharmacotherapy of gout – modern approaches and prospects. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(4):107-112. (In Russ.) https://doi.org/10.14412/1996-7012-2021-4-107-112
Views:
902
Email this article 